Self-Monitoring of Blood Pressure and Feed-back Using APP in TReatment of UnconTrolled Hypertension (SMART-BP): A Randomized Clinical Trial

Dong-Ju Choi, MD, PhD¹, Jin Joo Park, MD, PhD¹, Minjae Yoon, MD¹, Sung-Ji Park, MD, PhD², Sang-Ho Jo, MD, PhD³, Eung Ju Kim, MD, PhD³, Soo-Joong Kim, MD, PhD³, and Sungyoung Lee, PhD⁶

¹Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
²Division of Cardiology, Heart Vascular Stroke Institute, Samsung Medical Center/Sungkyunkwan University School of Medicine, Seoul, Korea
³Division of Cardiology, Hallym University Sacred Heart Hospital/Hallym University College of Medicine, Anyang, Korea
⁴Cardiovascular Center, Korea University Guro Hospital, Seoul, Korea
⁵Division of Cardiology, Kyung Hee University Hospital, Seoul, Korea
⁶Department of Computer Science and Engineering, Kyung Hee University, Yongin, Korea

AUTHOR’S SUMMARY

Because patients do not often know how to respond to the self-monitored blood pressure (SMBP) we developed a mobile application-based feed-back algorithm (SMBP-App) for tailored recommendations. Self-Monitoring of Blood pressure and Feed-back using APP in TReatment of UnconTrolled Hypertension (SMART-BP) is a prospective, randomized, open-label, multicenter trial to evaluate the efficacy of SMBP-App compared with SMBP alone. We will enroll 180 patients and patients in the SMBP-App group will receive specific recommendations in response to the obtained BP value. Home BP and drug adherence will be evaluated. We expect that SMBP-app to improve the treatment of hypertension.

ABSTRACT

Background and Objectives: Self-monitoring of blood pressure (SMBP) is a reliable method used to assess BP accurately. However, patients do not often know how to respond to the measured BP value. We developed a mobile application-based feed-back algorithm (SMBP-App) for tailored recommendations. In this study, we aim to evaluate whether SMBP-App is superior to SMBP alone in terms of BP reduction and drug adherence improvement in patients with hypertension.

Methods: Self-Monitoring of Blood pressure and Feed-back using APP in TReatment of UnconTrolled Hypertension (SMART-BP) is a prospective, randomized, open-label, multicenter trial to evaluate the efficacy of SMBP-App compared with SMBP alone. Patients with uncomplicated essential hypertension will be randomly assigned to the SMBP-App (90 patients) and SMBP alone (90 patients) groups. In the SMBP group, the patients will perform home BP measurement and receive the standard care, whereas in the SMBP-App group, the patients will receive additional recommendations from the application in response to the
obtained BP value. Follow-up visits will be scheduled at 12 and 24 weeks after randomization. The primary endpoint of the study is the mean home systolic BP. The secondary endpoints include the drug adherence, the home diastolic BP, home and office BP.

**Conclusions:** SMART-BP is a prospective, randomized, open-label, multicenter trial to evaluate the efficacy of SMBP-App. If we can confirm its efficacy, SMBP-App may be scaled-up to improve the treatment of hypertension.

**Trial Registration:** ClinicalTrials.gov Identifier: NCT04470284

**Keywords:** Hypertension; Blood pressure; Mobile health; Medication adherence

**INTRODUCTION**

High blood pressure (BP) is associated with increased cardio-, cerebro-, and renovascular complications. Its prevalence is increasing worldwide, and more than 50% of adults aged >60 years have hypertension in Korea. There is a large body of evidence that lowering BP reduces vascular events, and recently, even lower BP targets have been proposed. However, more than half of hypertensive patients do not achieve the required target BP. Although drug adherence is most crucial to achieve blood pressure control, only less than half of all hypertensive patients are considered adherent. Therefore, increasing drug adherence may alleviate the BP control rate.

Self-monitoring of blood pressure (SMBP) is known to reduce BP, although the exact mechanisms have not been elucidated. Possible explanations include increased awareness leading to better drug adherence and life-style modification by the patients themselves. Therefore, SMBP is recommended by the hypertension practice guidelines.

Although SMBP can reliably measure daily BP, the patient may not know the adequate response to the measured blood pressure value obtained. Tucker et al. showed in a systematic review and an individual patient data meta-analysis that SMBP alone could not achieve clinically significant BP control, unless it was accompanied by adequate co-interventions such as drug adjustment by the health care providers.

Although the direct intervention by health care professionals is the most effective means, it is also the most expensive one. Mobile health is a flexible platform with a low cost and an easy distribution. We developed a mobile health platform to provide tailored recommendations for hypertensive patients; the app gives an alert for BP measurement, records BP, and gives specific recommendations in response to the obtained value. In this prospective, randomized, open-label study, we will evaluate whether the mobile health app can help to reduce BP, to reach the BP target, and to increase the drug adherence compared to SMBP alone in hypertensive patients.

**METHODS**

**Ethical statement**

This clinical trial was approved by the institutional review board or ethics committee at each of the 5 participating hospitals; they are Seoul National University Bundang Hospital, Kyung Hee University Hospital, Korea University Guro Hospital, Samsung Medical Center, and

https://doi.org/10.4070/kcj.2022.0133
Hallym University Medical Center. The investigation will conform to the principles outlined in the Declaration of Helsinki. The study protocol has been registered in ClinicalTrials.gov (NCT04470284). All the authors are responsible for the study design, data acquisition, data analysis, and manuscript writing and editing. CONSORT checklist are included in the Supplementary Data 1.

**Overview**

The study flow is presented in Figure 1. This trial is a prospective, randomized, open-label, multicenter trial to evaluate the efficacy of SMBP with a mobile application-based feed-back algorithm (SMBP-App) compared with SMBP alone.

Patients with hypertension will be randomly assigned to the SMBP-App (intervention) group and SMBP-alone (control) groups. In the SMBP-alone group, the patients will perform home BP measurement and will receive the standard care. In the SMBP-App group, the patients will perform home BP measurement and will receive instructions from the mobile application in response to the obtained BP value.

The aim of this study will be to evaluate whether SMBP-App is superior to SMBP-alone in terms of BP reduction and drug adherence in patients with hypertension.

The trial has been approved by the relevant institutional review boards of each center. The protocol of this trial has been registered on ClinicalTrials.gov (registration number: NCT04470284). The study will comply with the Declaration of Helsinki.

---

**Figure 1.** Study flow chart.

SMBP = self-monitoring of blood pressure.
**Patients**

We will enroll patients with uncomplicated essential hypertension aged 19 years or older with a systolic BP of 140 mmHg or greater and a diastolic BP of 90 mmHg or greater while receiving at least one anti-hypertensive drug. The detailed inclusion and exclusion criteria are listed in Table 1.

**Blood pressure measurement device and mobile application**

For the current study, we will use a Bluetooth-enabled BP monitor UA-651BLE (A&D medical, Sidney, Australia). UA-651BLE is a commercially available BP cuff that has been approved for home use because of its high accuracy.31

We have developed the SMBP platform with a mobile application that can be downloaded from Google play-store and a lightweight web application eCRF-Lite System for physicians to observe the patients’ BP status (Figure 2A). The platform consists of four parts: the i) BP Recorder, ii) Knowledge Base Reasoner, iii) Database Lite, and iv) eCRF – Lite System (Supplementary Data 1). The “BP Recorder” connects the smartphone with the BP cuff via Bluetooth. Patients check their BP using the UA-651BLE BP monitor and system's core component. The “Knowledge Base Reasoner” asks the users about drug intake and symptoms (e.g., dizziness) based on BP values. The embedded algorithm in the Knowledge

---

Table 1. Inclusion and exclusion criteria

| Category               | Detailed Criteria                                                                                                                                 |
|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|
| **Inclusion criteria** | 1. Male and female patients with essential hypertension aged 19 years and above.                                                                      |
|                        | 2. Patients with essential hypertension who are taking one or more antihypertensive drugs.                                                             |
|                        | 3. Patients whose average systolic and diastolic BP measured 3 times on the reference arm in the sitting position during Visit 1 is greater than 140 |
|                        | mmHg and 90 mmHg, respectively.                                                                                                                      |
|                        | 4. Patients voluntarily consent to participate in this clinical trial.                                                                           |
|                        | 5. Patients who can use a smartphone.                                                                                                               |
| **Exclusion criteria** | 1. Patients with a history of secondary hypertension or suspected secondary hypertension, including coarctation of the aorta, primary         |
|                        | hyperaldosteronism, renal artery stenosis, Cushing’s syndrome, pheochromocytoma, and polycystic kidney disease.                                    |
|                        | 2. Patients with a mean systolic BP ≥200 mmHg or diastolic BP ≥110 mmHg at the screening visit.                                                       |
|                        | 3. Patients with ≥20 mmHg difference between the highest and the lowest sitting systolic BP or ≥10 mmHg difference between highest and lowest    |
|                        | diastolic BP, which is confirmed by triplicate measurements from the reference arm at screening.                                                   |
|                        | 4. Patients with uncontrolled diabetes (HbA1c ≥9.0%).                                                                                               |
|                        | 5. Patients who have been continuously taking other medications such as systemic steroids, thyroid hormones, oral contraceptives (except         |
|                        | for menopausal hormone replacement therapy), psychiatric drugs, non-steroidal anti-inflammatory drugs, sympathetic drugs, and immune        |
|                        | suppressants, which have the potential to affect BP.                                                                                                |
|                        | 6. Patients with symptomatic orthostatic hypotension.                                                                                               |
|                        | 7. Patients with a history of malignant tumors, including leukemia and lymphoma, within the past 5 years.                                          |
|                        | 8. Patients with a history of autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus.                               |
|                        | 9. Patients with clinically significant kidney and liver diseases, such as those on dialysis, liver cirrhosis, biliary obstruction, and hepatic |
|                        | failure, or those who show the following findings during the screening visit:                                                                   |
|                        | - Alanine transaminase or aspartate transaminase level is at least 3 times higher than the normal upper limit;                                     |
|                        | - Total bilirubin level is more than twice the normal upper limit;                                                                                |
|                        | - Blood urea nitrogen level is more than twice the normal upper limit;                                                                            |
|                        | - Alkaline phosphatase level is more than twice the normal upper limit;                                                                           |
|                        | - Creatinine clearance level is less than 10 mL/min.                                                                                                |
|                        | 10. Patients with a history of the following diseases in the past 6 months, which are determined to be clinically significant by the           |
|                        | investigator:                                                                                                                                     |
|                        | - Heart failure (NYHA class III and IV), ischemic heart diseases (coronary artery diseases, such as angina pectoris and myocardial infarction), |
|                        | peripheral vascular diseases, hemodynamically significant valve stenosis, and arrhythmia.                                                            |
|                        | - Severe cerebrovascular events, including stroke, cerebral infarction, and cerebral hemorrhage.                                                     |
|                        | 11. Patients with shock.                                                                                                                             |
|                        | 12. Patients with a history of alcohol or drug abuse.                                                                                               |
|                        | 13. Patients with potential pregnancy or breastfeeding.                                                                                                |
|                        | 14. Patients who will be judged as both legally and psychologically inadequate to participate in the clinical study by the investigator.        |
|                        | 15. Patients who have participated in clinical studies with other investigational drug products within 4 weeks prior to screening.            |

BP = blood pressure; NYHA = New York Heart Association.
Base Reasoner analyzes the data input and generates recommendation for the users, e.g., an alarm message, if an abnormal BP is detected. “Database” uses the SQLite database for the mobile app and the SQL Server for permanent storage on a cloud, and it stores the patients’ information using Data Model Manager, which controls the schema, whereas Data Access Object Management stores, modifies, and deletes data in form of instances. The details of the SMBP platform are explained in the Supplementary Data 1 of the manuscript. The application illustrates the trend of the recorded BP in days and weeks (Figure 2B).

**Study process**

This trial is a prospective, randomized, open-label, multicenter trial to evaluate the efficacy of SMBP-App compared with SMBP alone. Patients with hypertension will be randomly assigned to the SMBP-App (intervention) and SMBP alone (control) groups at 5 tertiary hospitals in Korea. After randomization, both groups will download the mobile application from the Google Play-Store and install it on their smartphones. After installation of the software, the application pairs automatically with the Bluetooth BP monitor. The difference in the mobile Apps is that the patients in the SMBP-App group will receive instructions from the mobile application in response to the obtained BP value. To be more specific, the SMBP-App will ask the patient’s opinion whether the measured BP is high, normal, or low, and whether the patients took the prescribed BP medication to enhance the awareness, vigilance, and drug adherence. In the SMBP-alone group, the patients will perform home BP measurement and receive the standard care.

Patients will continue their current antihypertensive drug for 24 weeks. Follow-up visits will be scheduled at 12 and 24 weeks after randomization. If BP value is not within the target range, the BP medication can be modified at the discretion of the treating physicians.
**Study endpoints**

The primary endpoint of the study is the mean home systolic BP change from randomization to 24 weeks. The key secondary endpoint is drug adherence from randomization to 24 weeks. Other secondary endpoints include the home diastolic BP from randomization to 12 weeks; 24-hour ambulatory systolic and diastolic BP reduction from 12 weeks to 24 weeks; sitting office systolic and diastolic BP at 24 weeks; home systolic and diastolic BP at 12 and 24 weeks; and drug adherence at 12 and 24 months.

**Randomization**

Randomization will be performed according to a pre-designed block randomization method. The randomization block will be generated by an independent statistician who is unrelated to this study using the SAS randomization program. Randomization will be performed in a 1:1 ratio, following the consecutive order.

**Measurement of drug adherence**

The drug adherence will be assessed with the “pill-count.” The patients will bring the remaining tablets to each scheduled visit during the clinical follow-up period. Examiners will count the number of returned drugs and calculate the drug adherence as follows:

\[
\text{Drug Adherence} = \frac{\text{Number of Pills Dispensed} - \text{Number of Pills Returned}}{\text{Number of Pills Dispensed}}
\]

If a discrepancy is present, the examiners will record the reason for the difference. The overall medication adherence should be at least 75% or more during the trial. Participants who will not satisfy this criterion will be excluded from the per-protocol (PP) analysis.

**Sample size calculation**

We assumed that the mean difference in systolic BP will be 3.4 mmHg with a standard deviation of ± 7.5 mmHg. With a two-sided alpha of 0.05 and power of 0.8, and a dropout rate of 15%, 180 patients (90 patients in the intervention and 90 patients in the control groups) will be required.

**Statistical analysis**

Data will be presented as numbers and frequencies for categorical variables and means ± standard deviations or median with interquartile range for continuous variables. For comparisons between the SMBP-App group and SMBP-only group, the \(\chi^2\) test or Fisher’s exact test will be used for the categorical variables, and the unpaired Student t-test for the continuous variables, as appropriate. Fisher’s exact test will be used when the expected frequencies is less than 5. In addition, analysis of covariance will also be conducted to analyze the BP change from baseline and follow-up.

The data will be primarily analyzed according to the intention-to-treat rule including all randomized participants. We also plan a PP analysis for patients with drug adherence of 75% or less. One-sided \(p\) values <0.05 will be considered statistically significant. The analyses will be performed by a professional statistician.
DISCUSSION

We developed a mobile health platform for a tailored intervention in hypertensive patients. The mobile application provides alerts for BP measurement reminders, tracks the BP and other biometric measurement, and visualizes the BP trend in easy-to-interpret graphs. It also provides specific instruction in response to the measured BP value, such as taking medication, if a high BP is measured. In this prospective, randomized, open-label study, we will evaluate whether SMBP-App can reduce BP and increase the drug adherence compared to SMBP alone.

Hypertension is identified as the leading risk factor for death and disability-adjusted life-years lost in 2010 according to the Global Burden of Disease Study. Hypertension is a modifiable risk factor and controlling hypertension is highly effective to prevent cardiovascular disease.

Self-monitoring of blood pressure alone
SMBP will increase the patients’ awareness; nonetheless, if the patients have an abnormal BP value, the patients may not know how to respond to the measured BP. Previous studies showed that SMBP increased the drug adherence; however, it happened only in combination with other adherence-enhancing strategies such as patient counseling by nurses, pharmacists, or a telephone-linked system.

Self-monitoring of blood pressure with the mobile health application
Currently, smartphones are available to most people, and there are many mobile health apps for the management of BP. These apps have similar interfaces including features of recording, tracking, analyzing, visualizing the results with intuitive graphics and tables, and even sharing the BP information using other mobile devices. Nonetheless, they do not provide pertinent instruction on how to act in response to the obtained BP value. Usually, the patients need to bring the BP data to the physician encounters to receive “feedback,” i.e., an appropriate response. This may take days, weeks, and even months, depending on the time interval for the routine clinic visit. Theoretically, the visualization of captured BP value and their temporal changes can alert the patients and change their behavior, such as improved drug adherence. However, the effect of the mobile health app on BP control was rather disappointing. Morawski et al. showed in a randomized, controlled study with 411 patients that patients randomized to use a smartphone app had only a slight improvement in self-reported medication adherence, but no change in the systolic BP was found compared with controls. By contrast, there was a greater reduction in BP when patients with SMBP were connected with health care professionals who may send text messages, or nurses who give treatment recommendations. Although this type of interaction between patients and health care professionals may be the ideal situation, it may not be realizable due to the high cost and shortage of healthcare providers.

Self-monitoring of blood pressure with the mobile application-based feedback algorithm
With enormous advancements in information and communication technologies artificial intelligence (AI) and clinical decision support system (CDSS) have proven efficacy. Our group developed AI-CDSS for diagnosis of heart failure with high diagnostic accuracy. In line with the application of information technology in medical practice, we developed a mobile application-based feedback algorithm for BP control. The conventional time interval between daily BP measurement and receiving feedback in the clinic is so long that the value of
daily BP measurement can be questioned. To provide immediate feedback, a “call center” can be operated that can monitor and respond to SMBP value by phone. However, its operation is very expensive. Here, we seek to determine whether the interaction between patients and health care professionals may be replaced by SMBP with the mobile application-based feedback algorithm. Mobile health app is a simple and cost-effective method, which is suitable for broad utilization and implementation among hypertension patients to monitor and record their BP at home. The SMBP-app will take over the “call center function” but provides immediate feedback at a low cost. Nonetheless, the interventions by CDSS application are simple. The SMBP-App captures, archives, and visualize the BP value like other conventional SMBP mobile health app; in addition, it educates the patients and reminds of taking their BP medication. These simple interventions will increase the alertness, awareness, and drug adherence substantially, eventually leading to better clinical outcomes. In addition, the SMBP app may have potential long-term cost benefit. It is well known that each 10 mmHg systolic BP reduction leads to 10% reduction in all-cause deaths, and 20% reduction heart failure. Heart failure is the leading cause for hospitalization and main health care burden in the modern society. To the best of our knowledge, our study is the first of its kind that evaluates the effectiveness of SMBP in conjunction with a designated mobile health app, which has a dedicated algorithm and a knowledge base to improve the BP control. If we can confirm its efficacy in this randomized controlled study, SMBP in conjunction with an appropriate mobile health app may be an effective solution to control hypertension.

**Limitations**

There are several limitations. The major limitation is that the newly developed algorithm that makes recommendations based on BP values has not been validated in the effectiveness and safety, which are also the main objective of these study. In addition, since we will only enroll patients who have a smartphone and are able to use it, the results of our trial may not be generalizable to other populations of individuals with poorly controlled hypertension, who may have different sociodemographic and comorbidity characteristics.

**ACKNOWLEDGMENTS**

We thank the MD Research Co. for the electronic case report form and data management.

**SUPPLEMENTARY MATERIAL**

Supplementary Data 1
Design and implementation of the SMBP platform with a mobile application.

Click here to view

**REFERENCES**

1. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13.

https://doi.org/10.4070/kcj.2022.0133
2. Park JK, Lim YH, Kim KS, et al. Changes in body fat distribution through menopause increase blood pressure independently of total body fat in middle-aged women: the Korean National Health and Nutrition Examination Survey 2007–2010. *Hypertens Res* 2013;36:444-9.

3. Correction to: heart disease and stroke statistics-2017 update: a report from the American Heart Association. *Circulation* 2017;136:e196.

4. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. *BMJ* 2000;321:412-9.

5. Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. *N Engl J Med* 2015;373:2103-16.

6. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. *JAMA* 2003;290:199-206.

7. Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. *Cochrane Database Syst Rev* 2014;(11):CD000011.

8. Fletcher BR, Hartmann-Boyce J, Hinton L, McManus RJ. The effect of self-monitoring of blood pressure on medication adherence and lifestyle factors: a systematic review and meta-analysis. *Am J Hypertens* 2015;28:1209-21.

9. Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension global hypertension practice guidelines. *J Hypertens* 2020;38:982-1004.

10. Tucker KL, Sheppard JP, Stevens R, et al. Self-monitoring of blood pressure in hypertension: a systematic review and individual patient data meta-analysis. *PLoS Med* 2017;14:e1002389.

11. Benetti E, Fania C, Palatini P. Validation of the A&D BP UA-651 device with a wide-range cuff for home blood pressure measurement according to the European Society of Hypertension International Protocol revision 2010. *Blood Press Monit* 2015;20:164-7.

12. Rinfret S, Lussier MT, Peirce A, et al. The impact of a multidisciplinary information technology-supported program on blood pressure control in primary care. *Circ Cardiovasc Qual Outcomes* 2009;2:170-7.

13. He J, Irazola V, Mills KT, et al. Effect of a community health worker-led multicomponent intervention on blood pressure control in low-income patients in argentina: a randomized clinical trial. *JAMA* 2017;318:1016-25.

14. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012;380:2224-60.

15. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ* 2000;321:405-12.

16. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA* 2003;289:2560-72.

17. Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. *Lancet* 2000;356:1955-64.

18. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. *JAMA* 1997;277:739-45.
19. Ogedegbe G, Schoenthaler A. A systematic review of the effects of home blood pressure monitoring on medication adherence. *J Clin Hypertens (Greenwich)* 2006;8:174-80.

PUBMED | CROSSREF

20. Morawski K, Ghazinouri R, Krumme A, et al. Association of a smartphone application with medication adherence and blood pressure control: the MedISAFE-BP randomized clinical trial. *JAMA Intern Med* 2018;178:802-9.

PUBMED | CROSSREF

21. Moore JO, Marshall MA, Judge D, et al. Technology-supported apprenticeship in the management of hypertension: a randomized controlled trial. *J Clin Outcomes Manag* 2014;21:110-22.

22. Choi DJ, Park JJ, Ali T, Lee S. Artificial intelligence for the diagnosis of heart failure. *NPJ Digit Med* 2020;3:54.

PUBMED | CROSSREF

23. Park JJ, Lee CJ, Park SJ, et al. Heart failure statistics in Korea, 2020: a report from the Korean Society of Heart Failure. *Int J Heart Fail* 2021;3:224.

CROSSREF